title: Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
mesh_terms: D005260:Female; D006801:Humans; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004149:Dioxoles / Q000008:administration & dosage; D000077143:Docetaxel; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D043823:Taxoids / Q000008:administration & dosage; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage; D000077606:Trabectedin; D017322:Clinical Trials, Phase II as Topic
chemical_list: D004149:Dioxoles; D000077143:Docetaxel; D043823:Taxoids; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin